# Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Source: https://onco.cc/trials/nct05287945/  
OnCo record `nct05287945` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Orellanine in renal cell carcinoma, run by Oncorena AB, now recruiting.

## Summary

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT05287945 by Oncorena AB, with 75 participants planned, started 2023-08-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Orellanine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05287945
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- Sponsor: Oncorena AB
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT05287945: https://clinicaltrials.gov/study/NCT05287945

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/nct05287945.json